Enzolytics Inc (ENZC)

[Timing101]

Mr Anderhale9... you bet ...
--
I am always interested in links.. .I know Harry has some history , but this is lining up with the Bioclonetics folks , who by all measures have the Integrity side locked up , easy to see on their backgrounds , DD on each is easy to find.
--
a. Legal side with Charles C
b. Medical side with Joe C
c. connections in Texas , no doubt there
d. Harry opening up and going to Texas , with the 8-k
e. LOI article .. I mean a lot of folks negative on that for whatever
reason and they are what they are until something happens. However,
one would not think that the Bioclonetics Team with their backgrounds
would waste their time doing that and putting it in print , PR and also
Included on the filing that Harry put out on OTC Markets and it was
SEC News side , plus the filing where it clearly shows that an SEC
Attorney was and is being used.
f. Harry did move all the ENZC office to Texas , someone is selling the office condo in Monrovia and it looks like him selling it , The new address is on an 8-k filing all good there and their new website shows TEXAS and the phone numbers now for ENZC are 972 Area Code which is TEXAS ... So Harry is now a Texan it appears.
2000 N. Sentra Express Way

Unit 104

Plano, Texas 75074
---
from the filing on 44/16/20
--
Enzolytics-News 4-16-2020



Plano, TX., April 16, 2020 /-- Enzolytics- (OTC Pink Sheet-ENZC) is pleased to update shareholders on the current corporate initiatives. The company has retained SEC counsel for the purpose of updating all corporate information, financials and to bring the company current from a public company perspective and allow the achievement of the company objectives.



The immediate goals include:



?Regain Current Status with OTC Markets

?Open operation in the Dallas, Tx area where the company has relocated

?Identify a CMO, Contract Manufacturing Organization, to produce the validation batch for Immunotech Laboratories BG-Europe.

?Assist Immunotech Laboratories BG-Europe in the registration of ImmunH as an Immunomodulator for HIV treatment.

?Further our development in North America of our Flagship HIV immune treatment compound IPF



As it relates to the CMO and production of the initial validation batch of our lead product ITV-1, which will be marketed in Europe as ImmunH through our partner, Immunotech Laboratories BG-Europe. This is for the treatment of HIV/Aids, and the validation batch production is for the purpose of Phase IV, as required by the regulatory agencies as part of the mass use permitting process. Upon a successful validation batch, the intention is for full commercialization in Eastern Europe initially, then expansion to additional markets. Enzolytics owns 49% of Immunotech Laboratories BG-Europe.



The company has made updates to its corporate website , www.enzolytics.com, and will continue to do so to provide further information to our shareholders.